Project Grant R01HL173315
Award Date
1/15/25
Completion Date
11/30/29
Dollars Obligated
$702K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This Project Grant award of $726,408 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to define the role of endothelial TFEB in mitigating cardiovascular toxicity induced by cancer therapies. The award recipient, the University of Cincinnati, will leverage its expertise in endothelial cell biology and transgenic mouse models to explore how modulating the TFEB pathway can protect against...
This Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Washington University to elucidate the mechanisms of cardiovascular toxicity associated with tyrosine kinase inhibitor (TKI) cancer treatments. The research aims to leverage patient-derived induced pluripotent stem cells to model TKI-induced vascular dysfunction and identify candidate compounds that can mitigate these adverse cardiovascular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
This $408,599 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the TGF-beta/SMAD3 pathway in endothelial damage and cardiac remodeling caused by doxorubicin chemotherapy. The research aims to assess how doxorubicin-induced endothelial reprogramming via this pathway contributes to the development of cardiomyopathy, and whether suppressing SMAD3...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,398,734 to the University of California, Merced to conduct research on understanding the role of the blood vascular system and endothelial cells in early thymus regeneration after cytotoxic treatments. The project aims to utilize novel intravital imaging techniques to directly analyze the live thymus and characterize the impact...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $549,665 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Maryland, Baltimore to conduct research on "Modulating the Resolution of Angiogenesis and Normalization of the Vasculature for Therapeutic Benefit." The goal is to advance the understanding of the fundamental processes that regulate the resolution of angiogenesis, in order to develop more effective therapeutic approaches for...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) totaling $706,220.00 supports research to elucidate the role of the nuclear pore protein NUP93 in regulating endothelial cell function and vascular health. The research aims to investigate how phosphorylation of NUP93 by the AKT signaling pathway impacts YAP localization and endothelial inflammation, as well as the in vivo importance of NUP93 phosphorylation in...
The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...